Unknown

Dataset Information

0

Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients.


ABSTRACT: Background:Epstein-Barr virus-associated gastric cancer (EBVaGC) has unique clinicopathologic features and our present understanding of its treatment outcome is limited. Here, we investigated the clinical outcomes of resectable and metastatic EBVaGC cases with regards to their respective treatment. Methods:We retrieved the data of EBVaGC patients treated at our center from October 2014 to June 2019. The primary endpoint was overall survival (OS). Secondary endpoints were disease-free survival (DFS) for stage?I-III patients, progression-free survival (PFS) and objective response rate (ORR) for stage IV patients. Results:Patients classified as stage?I-III accounted for 83.7% of the total 197 cases analyzed. Two patients had mismatched repair-deficiency. The 5-year OS rate of the entire cohort was 63.51% [95% (confidence interval (CI): 52.31-72.76%]. Tumor-node-metastasis (TNM) stage and gastric stump cancer were identified as independent prognostic factors for OS. The 3- and 5-year DFS rate for stage?I-III patients were 83.72% (95% CI: 75.86-89.19%) and 73.83% (95% CI: 60.39-83.32%), respectively. TNM stage?III, neural invasion, lymphovascular invasion, and baseline plasma EBV-DNA positive were correlated with shorter DFS. The ORR and disease control rate (DCR) for metastatic EBVaGC patients to first-line therapy were 29.0% and 90.3% (median PFS: 9.8?months), respectively, and to second-line therapy were 25.0% and 75.0%, respectively. Seven patients received anti-PD1 therapy and had an ORR of 28.5% and a median PFS of 2.8?months. Conclusions:EBVaGC patients have few metastases, long DFS, and high DCR. TNM stage and gastric stump cancer were independent prognostic factors for OS.

SUBMITTER: Qiu MZ 

PROVIDER: S-EPMC7338646 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients.

Qiu Miao-Zhen MZ   He Cai-Yun CY   Yang Da-Jun DJ   Zhou Da-Lei DL   Zhao Bai-Wei BW   Wang Xiao-Jian XJ   Yang Li-Qiong LQ   Lu Shi-Xun SX   Wang Feng-Hua FH   Xu Rui-Hua RH  

Therapeutic advances in medical oncology 20200706


<h4>Background</h4>Epstein-Barr virus-associated gastric cancer (EBVaGC) has unique clinicopathologic features and our present understanding of its treatment outcome is limited. Here, we investigated the clinical outcomes of resectable and metastatic EBVaGC cases with regards to their respective treatment.<h4>Methods</h4>We retrieved the data of EBVaGC patients treated at our center from October 2014 to June 2019. The primary endpoint was overall survival (OS). Secondary endpoints were disease-f  ...[more]

Similar Datasets

| S-EPMC5964025 | biostudies-literature
| S-EPMC3506544 | biostudies-literature
2019-06-08 | GSE132406 | GEO
| S-EPMC5438692 | biostudies-literature
| S-EPMC5518146 | biostudies-other
| S-EPMC5597738 | biostudies-literature
| S-EPMC5406766 | biostudies-literature
| S-EPMC7656552 | biostudies-literature
| S-EPMC5729479 | biostudies-literature
| S-EPMC5568662 | biostudies-other